Pharma Industry News

Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]